+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1



Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1



Chemmedchem 10(1): 158-163



Polo-like kinase 1 (PLK1) plays crucial functions in multiple stages of mitosis and is considered to be a potential drug target for cancer therapy. The functions of PLK1 are mediated by its N-terminal kinase domain and C-terminal polo-box domain (PBD). Most inhibitors targeting the kinase domain of PLK1 have a selectivity issue because of a high degree of structural conservation within kinase domains of all protein kinases. Here, we combined virtual and experimental screenings to identify green tea catechins as potent inhibitors of the PLK1 PBD. Initially, (-)-epigallocatechin, one of the main components of green tea polyphenols, was found to significantly block the binding of fluorescein-labeled phosphopeptide to the PBD at a concentration of 10 μm. Next, additional catechins were evaluated for their dose-dependent inhibition of the PBD and preliminary structure-activity relationships were derived. Cellular analysis further showed that catechins interfere with the proper subcellular localization of PLK1, lead to cell-cycle arrest in the S and G2M phases, and induce growth inhibition of several human cancer cell types, such as breast adenocarcinoma (MCF7), lung adenocarcinoma (A549), and cervical adenocarcinoma (HeLa). Our data provides new insight into understanding the anticancer activities of green tea catechins.

(PDF emailed within 0-6 h: $19.90)

Accession: 053666304

Download citation: RISBibTeXText

PMID: 25196850

DOI: 10.1002/cmdc.201402284


Related references

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic Chemistry 81: 278-288, 2018

Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investigational New Drugs 2019, 2019

A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1. Methods in Molecular Biology 795: 69-81, 2012

Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 21(9): 2623-2634, 2013

Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain. Chembiochem 17(8): 759-767, 2017

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors. Bioorganic and Medicinal Chemistry 26(12): 3429-3437, 2018

Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorganic and Medicinal Chemistry Letters 28(19): 3202-3205, 2018

Thymoquinone and Poloxin are slow-irreversible inhibitors to human Polo-like kinase 1 Polo-box domain. Journal of Medical Colleges of Pla 25(3): 136-142, 2010

Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules 24(8), 2019

A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Analytical Biochemistry 383(2): 205-209, 2008

Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells. Journal of Medicinal Chemistry 59(15): 7089-7096, 2016

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget 8(1): 1234-1246, 2016

Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 25(24): 6581-6588, 2017

Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer. Biological and Pharmaceutical Bulletin 40(9): 1454-1462, 2018

Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. Acs Chemical Biology 7(5): 805-810, 2012